TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

GlobeNewswire Inc. Logo GlobeNewswire Inc. By David Angulo
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

SCYNEXIS has transferred its BREXAFEMME New Drug Application to GSK, enabling potential regulatory interactions for relaunching the drug for vulvovaginal candidiasis. SCYNEXIS will receive potential net sales milestones and royalties from GSK.

Insights
RGTIW   neutral

Briefly mentioned in related articles without substantive analysis


SCYX   positive

Company completed strategic NDA transfer and will receive potential milestone payments and royalties from GSK